PROJECT SUMMARY
Studies in animal models have suggested 98% of the HIV reservoir to reside within the gut, yet most
studies of reservoir dynamics derive from peripheral blood. Unique challenges likely exist for purging the gut
reservoir as an HIV cure strategy. One of these is the high concentrations of the cytokine TGF? in this tissue,
as TGF? can have the combined undesired effects of reinforcing latency and dampening effector CD8+ T cells
that could otherwise recognize and eliminate reactivated cells. A second challenge for the design of a universal
HIV cure is latency-promoting effects of estrogen, which may necessitate different approaches for HIV cure in
infected men vs. women. In this study, we will recruit, among virally-suppressed people living with HIV
(PLWH), both pre- and post-menopausal women (who harbor different endogenous estrogen levels) and
clinically-matched men, for donation of gut biopsy and paired blood specimens. In Aim 1, we will characterize
at the single-cell level the transcriptomes, surface proteomes, and clonal expansion histories of the gut
reservoir cells, to better understand the mechanisms allowing for their persistence and to try to identify novel
biomarkers of these cells. In Aim 2, we will test ex vivo combinations of next-generation latency-reversal
agents (LRAs) – ones that have documented in vivo latency reversal activity and are promising agents to
achieve HIV cure through “shock and kill” – and use CyTOF and bioinformatics approaches to determine the
phenotypes of gut reservoir cells that do vs. do not reactivate in response to these treatments. These studies
will not only reveal how effective the various LRA combinations are against the gut reservoir, but also reveal
features of gut reservoir cells resistant to reactivation by these treatments which can be targeted using
adjunctive approaches. In Aim 3, we will develop and test “kill” approaches designed to eliminate reservoir
cells in the TGF?-rich environment of the gut, by 1) blocking TGF? signaling during recognition of infected cells
by HIV-specific CD8+ T cells, and 2) by transforming TGF? signal from an immunosuppressive to an activating
one, via engineering HIV-specific CAR T cells co-expressing a TGF?-41BB chimera. In addition to establishing
a better understanding of the gut reservoir and its maintenance (including through extensive comparison with
its blood counterpart) in both men and women living with HIV, this study will test multiple novel aspects of
“shock and kill” designed to eliminate the most abundant HIV reservoir in PLWH.